Drawing for AKOS

USPTO serial 97235741

AKOS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CHUNG, DIANA ALANA
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with AKOS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

RICHARD M. KLEIN

RICHARD M. KLEIN LIPPES MATHIAS LLPTHE HALLE BUILDING1228 EUCLID AVENUE, 5TH FLOORCLEVELAND, OH 44120

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical substances for use in the prevention, treatment and management of cancer, pain, mental health disorders, cancer related distress, anxiety, depression and post-traumatic stress disorder; pharmaceutical substances for use in the management of side effects from chemotherapy, radiation therapy, immunotherapy, and cancer treatmentABANDONED—
042Scientific and technological research services in the fields of medicine, biotechnology, and pharmaceuticals; scientific and technological research and drug development in the fields of cancer, pain, mental health disorders, cancer related distress, anxiety, depression and post-traumatic stress disorder; product development of pharmaceutical substances and medicines; pharmaceutical and medical research and development; pharmaceutical testing services; scientific laboratory services; research laboratory services relating to medicine, biotechnology, and pharmaceuticals; providing online non-downloadable software for data analytics, machine learning, knowledge management, and predictive analysis of biostatistical and treatment data in the field of medical researchABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 23, 2023MAB4ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION—
Aug 23, 2023ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Aug 23, 2023OP.TOPPOSITION TERMINATED NO. 999999—
Aug 23, 2023OP.SOPPOSITION SUSTAINED NO. 999999—
Jun 15, 2023OP.IOPPOSITION INSTITUTED NO. 999999—
Mar 20, 2023ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 21, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 18, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 17, 2023XAECEXAMINER'S AMENDMENT ENTERED—
Jan 17, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 17, 2023GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 17, 2023CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 9, 2023ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jan 9, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 6, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 6, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 6, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 5, 2022ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 16, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 16, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 16, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 11, 2022DOCKASSIGNED TO EXAMINER—
Jan 28, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 27, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance